NRG Oncology Study Results Indicate that Radiation and Chemotherapy After Surgery Could be a Viable Alternative to Radical Cystectomy for Patients with Recurrent Bladder Cancer
September 06, 2024
Read more »NRG Oncology Abstract Considered “Best of ASCO” for 2024 Shows Difference in Outcomes for Node-Negative Versus Node-Positive Pancreatic Cancer Patients when Adding Chemoradiation to Systemic Therapy
June 04, 2024
Read more »NRG Oncology Abstract Considered “Best of ASCO” for 2024 Shows Difference in Outcomes for Node-Negative Versus Node-Positive Pancreatic Cancer Patients when Adding Chemoradiation to Systemic Therapy
June 04, 2024
Read more »Principal Investigator Interview: RTOG 3521 Study of Combination Toripalimab and Chemotherapy in Recurrent Metastatic Nasopharyngeal Cancer
April 01, 2024
Read more »Principal Investigator Interview: The ‘KEYSTROKE’ RTOG 3507 Study of Pembrolizumab plus Stereotactic Re-Irradiation for Recurrent Head and Neck Cancer
April 01, 2024
Read more »Our Current RTOGF Communications Interns Discuss Their Experiences So Far: Rituraj Upadhyay, MD
January 16, 2024
Read more »Our Current RTOGF Communications Interns Discuss Their Experiences So Far: Danielle Cerbon, MD
January 16, 2024
Read more »Accepting Applications for the RTOGF Communications Internship (2024-2025)
January 08, 2024
Read more »Addition of EBRT to Brachytherapy Did Not Improve Outcomes for Men with Intermediate-Risk Prostate Cancer, Brachytherapy Alone Remains Standard of Care
June 15, 2023
Read more »Trial Does Not Improve Overall Survival, but Shows Improvements in Several Clinical Outcomes for Men with Intermediate-Risk Prostate Cancer
April 28, 2023
Read more »Patient-Reported Outcomes from a Study of Androgen Deprivation Therapy with Dose-Escalated Radiotherapy for Intermediate-Risk Prostate Cancer Show No Clinically Meaningful Differences in Scores at One Year Post-Treatment
April 28, 2023
Read more »RTOG 3508 Interim Analysis Yields no Survival Benefit with the Addition of Depatuxizumab-Mafodotin for EGRF-amplified Newly Diagnosed Glioblastoma
September 13, 2022
Read more »RTOG Foundation Announces Four New Committees and their Appointed Committee Leaders
August 04, 2022
Read more »NRG Oncology Study of Atezolizumab and Chemoradiation for Patients with Limited-Stage Small Cell Lung Cancer Completes Accrual
July 08, 2022
Read more »PSA-Based Endpoints Should Not Be Used as Surrogate Endpoints for Overall Survival in Men with Recurrent Prostate Cancer at this Time
June 29, 2022
Read more »Joint Final Report of Phase III trials Demonstrate Positive Outcomes from Combination of PCV Chemotherapy and RT in Patients with Anaplastic Oligodendroglial Tumors
June 28, 2022
Read more »NRG Oncology Study of Photon Versus Proton Therapy for Patients with Newly Diagnosed Glioblastoma Completes Accrual
May 12, 2022
The NRG-BN001 Study is the First NCI NCTN Proton Therapy Trial to Complete Accrual
Read more »NRG-BN011 Seeks to Improve Treatment Outcomes in a Substantial Subset of Glioblastoma Patients with Dual Alkylating Therapy
May 11, 2022
Read more »A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (NRG-BN010)
May 11, 2022
Read more »Exploring Options to Potentially Improve Treatment and Quality of Life for Patients in Two Head and Neck Cancer Trials
April 12, 2022
Read more »RTOG Foundation Seeks to Fill Four Committee Chair Positions - Application Deadline Extended
March 18, 2022
Applications deadline extended! Applications due March 31, 2022.
Read more »Spring 2022 Symposium & Workshop: Precision Medicine Applications in Radiation Oncology
November 22, 2021
Read more »Combining Radiotherapy and Immunotherapy in Patients with Extensive Stage Small Cell Lung Cancer (NRG-LU007, “the RAPTOR Trial”)
November 11, 2021
Read more »New Prostate Cancer Study Testing Higher-intensity Treatment for Patients with Higher Gene Risk Scores and Lower-intensity Treatment for Patients with Lower Gene Risk Scores (NRG-GU010, the GUIDANCE trial)
November 11, 2021
Read more »Hypofractionated Post-Operative Prostate Bed Radiotherapy Does Not Increase Patient-Reported Toxicity for Men with Prostate Cancer
October 25, 2021
Read more »Total Androgen Suppression with Dose-Escalated Radiotherapy Does Not Improve Overall Survival in Men with Intermediate-Risk Prostate Cancer: Results Highlight Need for Biomarker Studies
October 25, 2021
Read more »NSABP and RTOG Foundations Join GOG Foundation in Funding of the NRG Oncology Health Equity New Investigator Mentor Program
October 07, 2021
Read more »Breast Radiation following Lumpectomy Confirmed to Reduce Incidence of IBR for “Good Risk” DCIS
September 27, 2021
Read more »Survival Benefits Not Seen with Addition of Metformin to Concurrent Chemoradiation in Patients with Locally Advanced Non-Small Cell Lung Cancer
August 24, 2021
Read more »Testing if Sentinel Lymph Node Biopsy has Acceptable Cancer Control and Improves Quality of Life for People with Early-Stage Oral Cavity Cancer (NRG-HN006)
April 14, 2021
Read more »Comparing Hippocampal-Avoidant Whole Brain Radiotherapy to Stereotactic Radiosurgery for Patients with 10 or Fewer Brain Metastases from Small Cell Lung Cancer (NRG-CC009)
March 09, 2021
Read more »NRG Oncology’s Practice Changing Study on HA-WBRT plus Memantine Was Among Journal of Clinical Oncology’s Top 5 Downloads in 2020
February 18, 2021
Read more »